Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 10/20 | 0.64 |
| ▸ | EDNRB | P24530 | 10/20 | 0.57 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | TSPO | P30536 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14289223 | 0.86 | EDNRA (0.67) | EDNRAEDNRB | |
| SCHEMBL19569100 | 0.85 | EDNRA (0.64) | EDNRAEDNRBSLC6A2TSPODRD3 | |
| SCHEMBL9044009 | 0.85 | EDNRA (0.86) | EDNRAEDNRB | |
| SCHEMBL5632235 | 0.84 | EDNRB (0.74) | EDNRAEDNRBSLC6A2TSPODRD3 | |
| SCHEMBL9044364 | 0.81 | EDNRA (0.79) | EDNRAEDNRB | |
| SCHEMBL9044945 | 0.80 | EDNRA (0.89) | EDNRAEDNRB | |
| SCHEMBL9046585 | 0.80 | EDNRA (0.68) | EDNRAEDNRB | |
| SCHEMBL9495260 | 0.80 | EDNRA (0.68) | EDNRAEDNRB | |
| SCHEMBL9053381 | 0.80 | EDNRA (0.78) | EDNRAEDNRB | |
| SCHEMBL9052684 | 0.80 | EDNRA (0.68) | EDNRAEDNRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7285549-B2 | Sulfamides and their use as endothelin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-10-23 | — | — | US | disclosed |
| US-7285549-B2 | Sulfamides and their use as endothelin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-10-23 | — | — | US | disclosed |
| US-7285549-B2 | Sulfamides and their use as endothelin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-10-23 | — | — | US | disclosed |
| EP-1693372-A1 | Novel Sulfamides and their use as endothelin receptor antagonists | Actelion Pharmaceuticals Ltd. (CH) | 2006-08-23 | — | — | EP | disclosed |
| US-7094781-B2 | Sulfamides and their use as endothelin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2006-08-22 | — | — | US | disclosed |
| US-20060178365-A1 | Optionally oxidized 6-(2-(5-methylthio-2-pyrimidinyloxy)ethoxy)-2-phenylpyrimidin-4-yl-substituted sulfamides | BOLLI MARTIN | 2006-08-10 | — | — | US | disclosed |
| EP-1345920-B1 | NOVEL SULFAMIDES AND THEIR USE AS ENDOTHELIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2006-04-12 | — | — | EP | disclosed |
| US-20040077670-A1 | Novel sulfamides and their use as endothelin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2004-04-22 | — | — | US | disclosed |
| EP-1345920-A1 | NOVEL SULFAMIDES AND THEIR USE AS ENDOTHELIN RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2003-09-24 | — | — | EP | disclosed |
| WO-2002053557-A1 | NOVEL SULFAMIDES AND THEIR USE AS ENDOTHELIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2002-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178365-A1 | Optionally oxidized 6-(2-(5-methylthio-2-pyrimidinyloxy)ethoxy)-2-phenylpyrimidin-4-yl-substituted sulfamides | EDNRA, EDNRB, ECE2 | EDNRA 1/4885EDNRB 2/4885SLC6A2 2113/4885 |
| US-20040077670-A1 | Novel sulfamides and their use as endothelin receptor antagonists | EDNRA, EDNRB, ECE1 | EDNRA 1/4885EDNRB 2/4885SLC6A2 960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.